How to Partner in the Evolving Synthetic Biology Space

December 30, 2017 | State of the Market Report

Synthetic biology has long been touted as a revolution in the bio-based materials and chemicals space. However, in spite of considerable promise, developers have had difficulties translating lab results to commercialization. Nevertheless, synthetic biology companies rank as the three highest VC funded companies in 2016. Unlike previous developers, who focused on the entire value chain from strain development to commercial scale production, newer companies have tightened focus to aid on individual steps within strain development. In light of this changing synthetic biology landscape, this report highlights promising players and outlines partnership strategies.

Coverage Areas

  • Accelerating Materials Innovation
  • Emerging Ecosystems in Agrifood and Health

Table of Contents

  • Title page
  • The Historic Promise of Synthetic Biology
  • Assessing the Synthetic Biology Start-up Landscape
  • Picking a Partner Within Today‚Äôs Synthetic Biology Ecosystem

Lead Analyst

Gihan Hewage
Analyst

Contributors

Sara Olson, Ph.D.